{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:02:22Z","timestamp":1780646542638,"version":"3.54.1"},"reference-count":23,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015277","name":"Roche Products","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Obstet Med"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Casirivimab\/imdevimab (CAS\/IMD) comprises two monoclonal antibodies that neutralize SARS-CoV-2. Pregnant individuals were excluded from initial trials, limiting safety data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The COVID-19 International Drug Pregnancy Registry enrolled 53 pregnant women treated with CAS\/IMD, with 34 live births.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No safety concerns were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and conclusions<\/jats:title>\n                    <jats:p>The findings of the COVID-PR study support the safety of CAS\/IMD during pregnancy, adding to the growing body of evidence on COVID-19 treatments for this population. The available literature shows that CAS\/IMD is effective in preventing the progression to severe COVID-19 in pregnant individuals. The drugs are well-tolerated, and there is no compelling evidence of adverse maternal or neonatal outcomes. The results from the COVID-PR study are consistent with those of the broader literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1753495x251343113","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T03:08:54Z","timestamp":1750820934000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of casirivimab\/imdevimab (REGEN-COV) in pregnant individuals with COVID-19: Literature review and insights from the COVID-19 International Drug Pregnancy Registry"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-3429","authenticated-orcid":false,"given":"Diego F","family":"Wyszynski","sequence":"first","affiliation":[{"name":"Thermo Fisher Scientific Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Yau","sequence":"additional","affiliation":[{"name":"Product Development., Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Keebler","sequence":"additional","affiliation":[{"name":"Global Patient Safety, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Renz","sequence":"additional","affiliation":[{"name":"Clinical Research Group, Thermo Fisher Scientific Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ives","sequence":"additional","affiliation":[{"name":"Product Development Safety, Roche Products Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fitzgibbon","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee P","family":"Shulman","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization (WHO). WHO COVID-19 dashboard. 2024. https:\/\/covid19.who.int\/."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01620-z"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1753488"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2022.01.018"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-022-01829-4"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2021.08.025"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2022.100673"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004603"},{"key":"e_1_3_3_10_2","article-title":"Threatened miscarriage in a COVID-19 patient","volume":"14","author":"Momin A","year":"2022","unstructured":"Momin A, et al. Threatened miscarriage in a COVID-19 patient. Cureus 2022; 14: e31637.","journal-title":"Cureus"},{"key":"e_1_3_3_11_2","article-title":"Casirivimab and imdevimab for pregnant women hospitalized for severe coronavirus disease 2019","volume":"41","author":"Riccardo BA","year":"2022","unstructured":"Riccardo BA, et al. Casirivimab and imdevimab for pregnant women hospitalized for severe coronavirus disease 2019. Am J Perinatol 2022; 41: e612\u2013e616.","journal-title":"Am J Perinatol"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/jog.15338"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004689"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2022.013"},{"key":"e_1_3_3_15_2","article-title":"REGEN-CoV and COVID-19, update on the drug profile and FDA status: a mini-review and bibliometric study","volume":"10","author":"Mawazi SM","year":"2022","unstructured":"Mawazi SM, et al. REGEN-CoV and COVID-19, update on the drug profile and FDA status: a mini-review and bibliometric study. J Public Health Res 2022; 10.","journal-title":"J Public Health Res"},{"key":"e_1_3_3_16_2","first-page":"130","volume":"63","author":"Casirivimab and imdevimab (REGEN-COV) for post-exposure prophylaxis of COVID-19","year":"2021","unstructured":"Casirivimab and imdevimab (REGEN-COV) for post-exposure prophylaxis of COVID-19. Med Lett Drugs Ther 2021; 63: 130\u2013131.","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2022.09.017"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108163"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.202391"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1329"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01439-z"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01377-2"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwac046"},{"key":"e_1_3_3_24_2","first-page":"1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"29","author":"Page MJ","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J 2021; 29: 1\u20139.","journal-title":"Br Med J"}],"container-title":["Obstetric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753495X251343113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753495X251343113","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753495X251343113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:16:43Z","timestamp":1780643803000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753495X251343113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/1753495X251343113"],"URL":"https:\/\/doi.org\/10.1177\/1753495x251343113","relation":{},"ISSN":["1753-495X","1753-4968"],"issn-type":[{"value":"1753-495X","type":"print"},{"value":"1753-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]}}}